- CSR Summary Not Yet Available
- NCT00236353
- Primary Citation
- Data Specification Not Available
Trial Information
Generic NameRisperidoneProduct NameRISPERDAL CONSTA®Therapeutic AreaBehaviors and Mental DisordersEnrollment86% Female14.3%% WhiteN/A
Product ClassAtypical AntipsychoticsSponsor Protocol NumberRIS-USA-305Data PartnerJohnson & JohnsonCondition StudiedSchizophreniaMean/Median Age (Years)35
Supporting Documentation
- Clinical Study Report Available
Additional Information
Please note: individual participant-level data are not available for this trial. Only the synoptic report is available.
Approved Data Requests Associated with this Trial
- 2024-0556 : Heterogeneity of treatment effects during guaranteed antipsychotic maintenance treatment in schizophrenia as a window into the mechanisms of treatment
- 2022-4992 : Temporal trajectories of side-effects associated with antipsychotic treatment ? An individual participant data meta-analysis
- 2021-4705 : Inflammation and the Metabolic Syndrome in Psychosis
- 2019-3958 : Machine Learning for predicting treatment efficacy and clinical categorizations across mental health disorders.